Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07199010CT.gov Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression | — | Not Yet Recruiting | — | — | — |
NCT07154706CT.gov Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | — | Recruiting | — | — | — |
NCT07008287CT.gov Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases | — | Recruiting | — | — | — |
NCT06564324CT.gov A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | — | Recruiting | — | — | — |
NCT04919811CT.gov Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | — | Active Not Recruiting | — | — | — |
NCT04395677CT.gov A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | — | Active Not Recruiting | — | — | — |
NCT06841874CT.gov Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Taletrectinib (this asset) | Innovent Biologics (Suzhou) Co. Ltd. | P3 | CCC · 55 |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Endostatin | Henan Cancer Hospital | P4 | BBB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | BB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Taletrectinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | CCC · 51 |
| Breast Cancer | — | P2 | CC · 43 |
| Lung Disorder | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Taletrectinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/taletrectinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →